Pfizer wins Synthon jury trial over Norvasc drug


Pfizer Inc., the world's biggest drugmaker, said it won a jury finding that its Norvasc hypertension drug doesn't infringe a patent owned by Synthon BV. A federal jury in Alexandria, Virginia, also found that Synthon's patent was invalid, Pfizer said in a statement. Synthon, a closely held Dutch drugmaker, claimed Norvasc was made with a process covered by a patent issued in 2003. Pfizer said it had been using the process for making amlodipine, the chemical name for Norvasc, for 15 years. Norvasc is Pfizer's second best selling drug behind the cholesterol treatment Lipitor. Norvasc, which treats high blood pressure, had $4.7 billion in sales last year, according to figures complied by Bloomberg. „Today's unanimous decisions underscore our determination to defend our products against unwarranted attacks and to support research-based medical innovations that benefit millions of patients,” Allen Waxman, Pfizer's general counsel, said in the statement. Officials with Synthon's US offices in Chapel Hill, North Carolina, didn't immediately return a message seeking comment. (Bloomberg)


Consumer price levels below EU avg in 2020 Analysis

Consumer price levels below EU avg in 2020

Lawmakers approve 2022 budget Parliament

Lawmakers approve 2022 budget

Dentons rehires banking and finance partner Appointments

Dentons rehires banking and finance partner

Budapest launches revamped coupon card for visitors City

Budapest launches revamped coupon card for visitors


Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.